(Q37178648)

English

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients

scientific article published on 21 July 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

0 references

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Benita Wolf

3

0 references

author name string

Thomas Schwaab

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Adrian Schwarzer

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Todd S Crocenzi

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

John D Seigne

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Nancy A Crosby

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Bernard F Cole

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jan L Fisher

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jill C Uhlenhake

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Diane Mellinger

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Cathy Foster

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Zbigniew M Szczepiorkowski

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Susan M Webber

13

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Alan R Schned

14

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Robert D Harris

15

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Richard J Barth

16

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

John A Heaney

17

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Randolph J Noelle

18

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Marc S Ernstoff

19

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

21 July 2009

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

15

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

15

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

4986-4992

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

Forecasting the cytokine storm following systemic interleukin (IL)-2 administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

Dendritic cell immunotherapy: mapping the way.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8+T-Cell Function in Melanoma Patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

Dendritic cells and the control of immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

Mig and IP-10: CXC chemokines that target lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

The dendritic cell system and its role in immunogenicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

6 September 2017

Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

14 September 2017

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

26 June 2018

Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

26 June 2018

Characterization of a Human Renal Cell Carcinoma Specific Cytotoxic CD8+ T Cell Line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

26 June 2018

Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

3 September 2018

Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

3 September 2018

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

3 September 2018

Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

3 September 2018

IL-2 overcomes the unresponsiveness but fails to reverse the regulatory function of antigen-induced T regulatory cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

3 September 2018

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

3 September 2018

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

3 September 2018

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

3 September 2018

Use of cell-tracking dyes to determine proliferation precursor frequencies of antigen-specific T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

3 September 2018

Decreased antigen presentation by dendritic cells in patients with breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3775650

3 September 2018

Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcom

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal recruitment and activation of dendritic cells within renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Self-recognition and tumor response to immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo description of dendritic cells in human renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vaccine therapy for renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An optimized method for the functional analysis of human regulatory T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19622576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-08-3240

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37178648&oldid=1790163393"